Jung Kim - ABL Bio MD COO

298380 Stock  KRW 27,050  600.00  2.17%   

Insider

Jung Kim is MD COO of ABL Bio
Phone82 31 8018 9800
Webhttp://www.ablbio.com

ABL Bio Management Efficiency

The company has return on total asset (ROA) of (0.3051) % which means that it has lost $0.3051 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 5.5983 %, meaning that it generated $5.5983 on every $100 dollars invested by stockholders. ABL Bio's management efficiency ratios could be used to measure how well ABL Bio manages its routine affairs as well as how well it operates its assets and liabilities.
ABL Bio has accumulated 72.32 M in total debt with debt to equity ratio (D/E) of 1.4, which is about average as compared to similar companies. ABL Bio has a current ratio of 14.42, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist ABL Bio until it has trouble settling it off, either with new capital or with free cash flow. So, ABL Bio's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like ABL Bio sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for ABL to invest in growth at high rates of return. When we think about ABL Bio's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 8 records

INSIDER Age

JaiHyun KwonGenexine
N/A
Jungwon WooGenexine
N/A
Kyu KimGenexine
N/A
You SuhGenexine
N/A
Sung LeeGenexine
N/A
Young SungGenexine
67
Jae ParkGenexine
N/A
Sung CPAGenexine
N/A
ABL Bio Inc., a biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. Its pipeline drugs include ABL001, cancer immunotherapy, ADC, and ABL301. ABL Bio is traded on Korean Securities Dealers Automated Quotations in South Korea. ABL Bio (298380) is traded on KOSDAQ in Korea and employs 7 people.

Management Performance

ABL Bio Leadership Team

Elected by the shareholders, the ABL Bio's board of directors comprises two types of representatives: ABL Bio inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ABL. The board's role is to monitor ABL Bio's management team and ensure that shareholders' interests are well served. ABL Bio's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ABL Bio's outside directors are responsible for providing unbiased perspectives on the board's policies.
Jung Kim, MD COO
Jaecheon Lee, MD CFO
Jae Jung, MD Discovery
Jong Kim, MD Devel
Sang Lee, Founder CEO
You WeonKyoo, Head MD
Jong Won, Head Devel

ABL Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ABL Bio a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with ABL Bio

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ABL Bio position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ABL Bio will appreciate offsetting losses from the drop in the long position's value.

Moving together with ABL Stock

  0.62207940 Samsung BiologicsPairCorr
  0.89326030 Sk BiopharmaceuticalsPairCorr
The ability to find closely correlated positions to ABL Bio could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ABL Bio when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ABL Bio - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ABL Bio to buy it.
The correlation of ABL Bio is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ABL Bio moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ABL Bio moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ABL Bio can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Other Information on Investing in ABL Stock

ABL Bio financial ratios help investors to determine whether ABL Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in ABL with respect to the benefits of owning ABL Bio security.